查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649460

神经系统疾病诊断与治疗市场预测（2025-2030）

Neurological Disorder Diagnostics Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

神经系统疾病诊断和治疗市场预计将以 5.68% 的复合年增长率成长，从 2025 年的 143.4 亿美元增长到 2030 年的 189.03 亿美元。

神经系统疾病是一种影响神经系统功能的疾病，包括大脑、脊髓和神经。这些病症包括多种疾病，包括阿兹海默症和帕金森氏症等神经退化性疾病、肌肉萎缩症营养不良症和肌肉萎缩侧索硬化症等神经肌肉疾病、脊柱裂和脊髓神经病变等脊椎疾病，以及週边神经病变和腕管综合症等周边神经问题。神经系统疾病诊断市场包括诊断这些疾病所使用的所有工具、技术、设备、产品和服务。这包括磁振造影（MRI）、电脑断层扫描（CT）、神经影像生物标记、超音波系统、血液和脑脊髓液生物标记检测、基因检测和用于资料分析的可穿戴设备等技术。有几个因素推动了神经疾病诊断市场的成长。这在很大程度上是由于阿兹海默症、失智症和帕金森氏症等神经系统疾病的发生率不断上升。此外，事故造成脑损伤的增加进一步刺激了市场需求。政府、非政府组织和机构为提高人们对早期筛检神经系统健康重要性的认识而做出的努力也推动了早期诊断的需求。此外，研发投入的增加也推动了诊断技术和流程的进步。人工智慧（AI）和机器学习技术的日益普及也透过提供更准确的资料分析推动了市场成长。此外，各国政府（特别是新兴国家）增加对医疗保健的投资，也进一步支持了市场扩张。

神经疾病诊断市场驱动因素：

  • 神经系统疾病发生率上升：全球神经系统疾病发病率上升是由多种因素造成的，包括以压力为特征的生活方式的改变、心理健康问题、身体活动减少、对数位科技的依赖、人口老化和环境污染。这些因素导致阿兹海默症和帕金森氏症等疾病的发病率迅速上升，增加了对诊断工具和技术的需求。根据阿兹海默症协会的资料，约有480万65岁及以上的美国阿兹海默症而患有失智症，美国失智症患者总合690万人。

影响神经诊断市场的地理趋势：

  • 亚太地区快速成长：神经疾病诊断市场分为北美、南美、欧洲、中东和非洲、亚太等地区。预计预测期内亚太地区将成为该市场成长最快的地区。这一成长主要由中国、韩国和印度等新兴国家推动，这些国家正在加强医疗保健基础设施，以应对日益增长的神经系统疾病发病率。

例如，预计2022年中国将有约480万新发癌症病例，257万人死于癌症。这凸显了透过先进的诊断技术开发个人化医疗的迫切需求。另一方面，由于北美拥有先进的医疗保健基础设施，预计将占据神经系统疾病诊断市场的大部分份额。神经系统疾病的高发生率也促成了这个优势。预计到2024年，阿兹海默症导致失智症的人数将达到690万人。总而言之，神经诊断市场正在经历强劲增长，其推动力包括全球神经系统疾病患病率上升、人们对早期诊断认识的不断提高、诊断工具和流程的技术进步、政府在医疗保健投资方面的支持性倡议以及有利的市场趋势（尤其是在亚太地区），这些都在强化不断扩大的市场环境。

为什么要购买这份报告？

  • 深刻分析：获得深入的市场洞察，涵盖主要和新兴地区，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略与市场占有率分析
  • 细分和区域分析，包括收益成长和预测国家
  • 公司概况（策略、产品、财务、主要发展等）

神经诊断和治疗市场细分如下：

依疾病类型

  • 神经退化性疾病
  • 神经肌肉疾病
  • 脊椎疾病
  • 週边神经疾病

依技术分类

  • 诊断影像技术
  • 体外诊断技术

按最终用户

  • 医院和诊所
  • 诊断中心
  • 其他的

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他的
  • 中东和非洲
  • 沙乌地阿拉伯
  • UAE
  • 其他的
  • 亚太地区
  • 中国
  • 日本
  • 韩国
  • 澳洲
  • 印度
  • 印尼
  • 泰国
  • 其他的

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章 神经系统疾病诊疗市场（依疾病类型）

  • 介绍
  • 神经退化性疾病
  • 神经肌肉疾病
  • 脊椎疾病
  • 週边神经病变

第六章 神经系统疾病诊断与治疗市场（依技术）

  • 介绍
  • 成像技术
  • 体外诊断技术

第七章 神经系统疾病诊断与治疗市场（依最终使用者）

  • 介绍
  • 医院和诊所
  • 诊断中心
  • 其他的

第八章 神经系统疾病诊疗市场区域分布

  • 介绍
  • 北美洲
    • 依疾病类型
    • 依技术分类
    • 按最终用户
    • 按国家
  • 南美洲
    • 依疾病类型
    • 依技术分类
    • 按最终用户
    • 按国家
  • 欧洲
    • 依疾病类型
    • 依技术分类
    • 按最终用户
    • 按国家
  • 中东和非洲
    • 依疾病类型
    • 依技术分类
    • 按最终用户
    • 按国家
  • 亚太地区
    • 依疾病类型
    • 依技术分类
    • 按最终用户
    • 按国家

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • GE Healthcare
  • Siemens Healthcare
  • FUJIFILM Holdings Corporation
  • Koninklijke Philips NV
  • Thermo Fisher Scientific Inc.
  • Masimo
  • Medtronic
  • Abbott Laboratories
简介目录
Product Code: KSI061617236

The neurological disorder diagnostics treatment market is expected to grow at a CAGR of 5.68%, reaching a market size of US$18.903 billion in 2030 from US$14.340 billion in 2025

Neurological disorders are conditions that impact the functioning of the nervous system, including the brain, spinal cord, and nerves. These disorders encompass a range of conditions, such as neurodegenerative diseases like Alzheimer's and Parkinson's disease, neuromuscular disorders like muscular dystrophy and amyotrophic lateral sclerosis, spine conditions such as spina bifida and spinal cord injuries, as well as peripheral nerve issues like peripheral neuropathy and carpal tunnel syndrome.The neurological disorder diagnostics market includes all tools, techniques, devices, products, and services used to diagnose these conditions. This encompasses technologies such as magnetic resonance imaging (MRI), computed tomography (CT), neuroimaging biomarkers, ultrasound systems, blood and cerebrospinal fluid tests for biomarkers, genetic testing, and wearable devices for data analysis. Key settings for these diagnostics include hospitals, clinics, and diagnostic centers.Several factors are driving the growth of the neurological disorder diagnostics market. The rising prevalence of neurological diseases such as Alzheimer's, dementia, and Parkinson's disease is a significant contributor. Additionally, the increasing number of brain injuries due to accidents further boosts market demand. Efforts by governments, NGOs, and institutions to raise awareness about the importance of early screening for neurological health are also propelling demand for early diagnosis. Furthermore, increased investment in research and development has led to advancements in diagnostic technologies and processes. The growing adoption of artificial intelligence (AI) and machine learning technologies enhances market growth by providing more accurate data analysis. Additionally, rising healthcare investments by governments-particularly in emerging countries-are further fueling market expansion.

Drivers of the Neurological Disorder Diagnostics Market:

  • Rising Prevalence of Neurological Disorders: The global increase in neurological disorders is driven by various factors including lifestyle changes characterized by stress, mental health issues, reduced physical activity, reliance on digital technology, an aging population, and environmental pollution. These factors contribute to a surge in diseases like Alzheimer's and Parkinson's disease, thereby increasing the demand for diagnostic tools and techniques. According to data from the Alzheimer's Association, approximately 4.8 million Americans aged 65 and older have dementia due to Alzheimer's disease, with a total of 6.9 million individuals affected by dementia in the U.S.

Geographical Trends Shaping the Neurological Disorder Diagnostics Market:

  • Rapid Growth in Asia-Pacific: The neurological disorder diagnostics market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia-Pacific. During the forecast period, Asia-Pacific is anticipated to be the fastest-growing region in this market. This growth is driven by emerging economies such as China, South Korea, and India, which are enhancing their healthcare infrastructure to address the increasing prevalence of neurological disorders.

For instance, it was estimated that around 4.8 million new cancer cases and 2.57 million cancer deaths occurred in China in 2022. This highlights the critical need for personalized medicine development through advanced diagnostic technologies.Meanwhile, North America is expected to maintain a significant share of the neurological disorder diagnostics market due to its advanced healthcare infrastructure. The high prevalence of neurological disorders contributes to this dominance; projections indicate that there will be 6.9 million dementia patients due to Alzheimer's in 2024. Additionally, government investments and private sector initiatives are driving continued regional expansion.In summary, the neurological disorder diagnostics market is experiencing robust growth driven by rising prevalence of neurological disorders globally, increased awareness about early diagnosis, technological advancements in diagnostic tools and processes, supportive governmental initiatives in healthcare investment, and favorable geographical trends-particularly within Asia-Pacific-that enhance this expanding market landscape.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Neurological Disorder Diagnostics Treatment Market has been segmented as following:

By Type of Disorder

  • Neurodegenerative Disorders
  • Neuromuscular Disorders
  • Spinal Disorders
  • Peripheral Nerve Disorder

By Technology

  • Imaging Techniques
  • In Vitro Diagnostic Techniques

By End-User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY TYPE OF DISORDER

  • 5.1. Introduction
  • 5.2. Neurodegenerative Disorders
  • 5.3. Neuromuscular Disorders
  • 5.4. Spinal Disorders
  • 5.5. Peripheral Nerve Disorder

6. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Imaging Techniques
  • 6.3. In Vitro Diagnostic Techniques

7. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Diagnostic Centers
  • 7.4. Others

8. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type of Disorder
    • 8.2.2. By Technology
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Type of Disorder
    • 8.3.2. By Technology
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Type of Disorder
    • 8.4.2. By Technology
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Type of Disorder
    • 8.5.2. By Technology
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Type of Disorder
    • 8.6.2. By Technology
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. Australia
      • 8.6.4.5. India
      • 8.6.4.6. Indonesia
      • 8.6.4.7. Thailand
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. GE Healthcare
  • 10.2. Siemens Healthcare
  • 10.3. FUJIFILM Holdings Corporation
  • 10.4. Koninklijke Philips N.V.
  • 10.5. Thermo Fisher Scientific Inc.
  • 10.6. Masimo
  • 10.7. Medtronic
  • 10.8. Abbott Laboratories